Pembrolizumab Combo Falls Short in Phase 3 Frontline Urothelial Carcinoma Trial
Adding pembrolizumab to chemotherapy did not lead to a statistically significant improvement in overall survival or progression-free survival in patients with advanced or metastatic urothelial carcinoma, according to findings from the phase 3 KEYNOTE-361 trial.
Source: OncLive